Robert W. Baird Forecasts Strong Price Appreciation for Cooper Companies (NASDAQ:COO) Stock

Cooper Companies (NASDAQ:COO) had its price target hoisted by stock analysts at Robert W. Baird from $85.00 to $98.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the medical device company’s stock. Robert W. Baird’s target price would suggest a potential upside of 27.22% from the company’s previous close.

A number of other research analysts also recently commented on COO. KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a research note on Friday. JPMorgan Chase & Co. lowered their target price on shares of Cooper Companies from $76.00 to $66.00 and set a “neutral” rating for the company in a report on Thursday, August 28th. Barclays assumed coverage on shares of Cooper Companies in a research note on Monday, October 13th. They set an “overweight” rating and a $85.00 price target on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Cooper Companies in a research note on Monday. Finally, Morgan Stanley set a $76.00 price objective on Cooper Companies and gave the stock an “equal weight” rating in a report on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $87.08.

Cooper Companies Trading Up 1.4%

Shares of COO opened at $77.03 on Friday. Cooper Companies has a fifty-two week low of $61.78 and a fifty-two week high of $104.47. The company has a market capitalization of $15.31 billion, a PE ratio of 37.95, a price-to-earnings-growth ratio of 1.87 and a beta of 1.05. The stock has a fifty day moving average of $72.01 and a two-hundred day moving average of $71.74. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 2.12.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. The business had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The business’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.04 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. As a group, analysts forecast that Cooper Companies will post 3.98 EPS for the current year.

Cooper Companies announced that its board has initiated a stock repurchase program on Wednesday, September 17th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical device company to purchase up to 15.4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

Insider Activity at Cooper Companies

In other Cooper Companies news, Director Lawrence Erik Kurzius purchased 2,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The stock was purchased at an average cost of $68.39 per share, with a total value of $136,780.00. Following the transaction, the director owned 5,777 shares in the company, valued at approximately $395,089.03. This trade represents a 52.95% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.98% of the company’s stock.

Institutional Investors Weigh In On Cooper Companies

Large investors have recently modified their holdings of the stock. Zions Bancorporation National Association UT acquired a new position in shares of Cooper Companies in the first quarter valued at $33,000. Bell Investment Advisors Inc lifted its holdings in shares of Cooper Companies by 106.3% during the 3rd quarter. Bell Investment Advisors Inc now owns 425 shares of the medical device company’s stock worth $29,000 after acquiring an additional 219 shares during the period. GKV Capital Management Co. Inc. bought a new position in shares of Cooper Companies during the 1st quarter worth about $40,000. J.Safra Asset Management Corp boosted its position in shares of Cooper Companies by 204.8% during the 2nd quarter. J.Safra Asset Management Corp now owns 506 shares of the medical device company’s stock valued at $36,000 after acquiring an additional 340 shares in the last quarter. Finally, CYBER HORNET ETFs LLC bought a new stake in Cooper Companies in the second quarter valued at about $36,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.